Additionally, the 36-month beta value for CYCC is 0.47. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CYCC is 23.36M and currently, short sellers hold a 0.12% ratio of that float. The average trading volume of CYCC on May 07, 2025 was 2.48M shares.
CYCC) stock’s latest price update
The stock price of Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) has jumped by 18.43 compared to previous close of 0.30. Despite this, the company has seen a gain of 16.52% in its stock price over the last five trading days. globenewswire.com reported 2025-05-06 that KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, “Waste-To-Resource” services and real estate development and construction.
CYCC’s Market Performance
CYCC’s stock has risen by 16.52% in the past week, with a monthly rise of 65.42% and a quarterly rise of 1.03%. The volatility ratio for the week is 21.75% while the volatility levels for the last 30 days are 21.17% for Cyclacel Pharmaceuticals Inc The simple moving average for the past 20 days is 42.55% for CYCC’s stock, with a -44.73% simple moving average for the past 200 days.
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
ROTH Capital, on the other hand, stated in their research note that they expect to see CYCC reach a price target of $24. The rating they have provided for CYCC stocks is “Buy” according to the report published on April 27th, 2020.
CYCC Trading at 26.80% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.52% of loss for the given period.
Volatility was left at 21.17%, however, over the last 30 days, the volatility rate increased by 21.75%, as shares surge +88.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.15% upper at present.
During the last 5 trading sessions, CYCC rose by +16.52%, which changed the moving average for the period of 200-days by -79.30% in comparison to the 20-day moving average, which settled at $0.2483. In addition, Cyclacel Pharmaceuticals Inc saw -5.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCC starting from Lazar David E., who sale 194,628,820 shares at the price of $0.03 back on Feb 26 ’25. After this action, Lazar David E. now owns 0 shares of Cyclacel Pharmaceuticals Inc, valued at $5,507,996 using the latest closing price.
Stock Fundamentals for CYCC
Current profitability levels for the company are sitting at:
- -347.19 for the present operating margin
- 0.91 for the gross margin
The net margin for Cyclacel Pharmaceuticals Inc stands at -215.28. The total capital return value is set at 6.87. Equity return is now at value -807.39, with -173.81 for asset returns.
Currently, EBITDA for the company is -12.0 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 3065.31. The receivables turnover for the company is 0.18for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.59.
Conclusion
In conclusion, Cyclacel Pharmaceuticals Inc (CYCC) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
